Timely and individualized heart failure management: need for implementation into the new guidelines.
Heart failure
Management
Outcomes
Treatment
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
30
03
2021
accepted:
30
04
2021
pubmed:
14
5
2021
medline:
30
12
2021
entrez:
13
5
2021
Statut:
ppublish
Résumé
Due to remarkable improvements in heart failure (HF) management over the last 30 years, a significant reduction in mortality and hospitalization rates in HF patients with reduced ejection fraction (HFrEF) has been observed. Currently, the optimization of guideline-directed chronic HF therapy remains the mainstay to further improve outcomes for patients with HFrEF to reduce mortality and HF hospitalization. This includes established device therapies, such as implantable defibrillators and cardiac resynchronization therapies, which improved patients' symptoms and prognosis. Over the last 10 years, new HF drugs have merged targeting various pathways, such as those that simultaneously suppress the renin-angiotensin-aldosterone system and the breakdown of endogenous natriuretic peptides (e.g., sacubitril/valsartan), and those that inhibit the I
Identifiants
pubmed: 33983472
doi: 10.1007/s00392-021-01867-2
pii: 10.1007/s00392-021-01867-2
pmc: PMC8117452
doi:
Substances chimiques
Cardiovascular Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1150-1158Informations de copyright
© 2021. The Author(s).
Références
Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39
pubmed: 30424892
doi: 10.1016/S0140-6736(18)32590-X
pmcid: 30424892
Fitchett D, Inzucchi SE, Cannon CP et al (2019) Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation 139:1384–1395
pubmed: 30586757
doi: 10.1161/CIRCULATIONAHA.118.037778
pmcid: 30586757
McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008
pubmed: 31535829
doi: 10.1056/NEJMoa1911303
pmcid: 31535829
Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424
pubmed: 32865377
doi: 10.1056/NEJMoa2022190
pmcid: 32865377
Jhund PS, Solomon SD, Docherty KF et al (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction. Circulation 143:298–309
pubmed: 33040613
doi: 10.1161/CIRCULATIONAHA.120.050391
pmcid: 33040613
Zannad F, Ferreira JP, Pocock SJ et al (2020) Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Reduced trial. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.120.051685
doi: 10.1161/CIRCULATIONAHA.120.051685
pubmed: 33284652
pmcid: 7834911
Petrie MC, Verma S, Docherty KF et al (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323:1353–1368
pubmed: 32219386
pmcid: 7157181
doi: 10.1001/jama.2020.1906
Anker SD, Butler J, Filippatos G, EMPEROR-Reduced Trial Committees and Investigators et al (2020) Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status—results from the EMPEROR-Reduced Trial. Circulation 143(4):337–349
pubmed: 33175585
pmcid: 7834911
doi: 10.1161/CIRCULATIONAHA.120.051824
Packer M, Anker SD, Butler J et al (2021) Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 42:671–680
pubmed: 33459776
pmcid: 7878011
doi: 10.1093/eurheartj/ehaa968
Chen X, Cui X, Thunström E et al (2021) Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction. Clin Res Cardiol. https://doi.org/10.1007/s00392-020-01790-y
doi: 10.1007/s00392-020-01790-y
pubmed: 33846840
Gheorghiade M, Vaduganathan M, Ambrosy A et al (2013) Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail Rev 18:107–122
pubmed: 22581217
doi: 10.1007/s10741-012-9315-1
Komajda M, Böhm M, Borer JS et al (2014) Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. Eur J Heart Fail 16:810–816
pubmed: 24961493
doi: 10.1002/ejhf.114
pmcid: 24961493
Tikkanen I, Narko K, Zeller C et al (2015) Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 38:420–428
pubmed: 25271206
doi: 10.2337/dc14-1096
pmcid: 25271206
Kario K, Okada K, Kato M et al (2018) 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA Study. Circulation 139:2089–2897
pmcid: 6493695
doi: 10.1161/CIRCULATIONAHA.118.037076
Serenelli M, Böhm M, Inzucchi SE et al (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and prevention of adverse outcomes in heart failure trial (DAPA-HF). Eur Heart J 41:3402–3418
pubmed: 32820334
pmcid: 7550197
doi: 10.1093/eurheartj/ehaa496
McEwan P, Darlington O, McMurray JJV et al (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. Eur J Heart Fail 22:2147–2156
pubmed: 32749733
doi: 10.1002/ejhf.1978
pmcid: 32749733
Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384:129–139
pubmed: 33200891
doi: 10.1056/NEJMoa2030186
pmcid: 33200891
Bhatt DL, Szarek M, Steg PG et al (2020) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. https://doi.org/10.1056/NEJMoa2030183
doi: 10.1056/NEJMoa2030183
pubmed: 33200892
pmcid: 33200892
Follmann M, Ackerstaff J, Redlich G et al (2017) Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem 60:5146–5161
pubmed: 28557445
doi: 10.1021/acs.jmedchem.7b00449
pmcid: 28557445
Gheorghiade M, Greene SJ, Butler J et al (2015) Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA 314:2251–2262
pubmed: 26547357
doi: 10.1001/jama.2015.15734
pmcid: 26547357
Armstrong PW, Pieske B, Anstrom KJ et al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883–1893
pubmed: 32222134
doi: 10.1056/NEJMoa1915928
pmcid: 32222134
Malik FI, Hartman JJ, Elias KA et al (2011) Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331:1439–1443
pubmed: 21415352
pmcid: 4090309
doi: 10.1126/science.1200113
Teerlink JR, Felker GM, McMurray JJ et al (2016) Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388:2895–2903
pubmed: 27914656
doi: 10.1016/S0140-6736(16)32049-9
pmcid: 27914656
Teerlink JR, Diaz R, Felker GM et al (2020) Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail 22:2160–2171
pubmed: 32985088
doi: 10.1002/ejhf.2015
pmcid: 32985088
Teerlink JR, Diaz R, Felker GM et al (2020) Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. https://doi.org/10.1056/NEJMoa2025797
doi: 10.1056/NEJMoa2025797
pubmed: 33185990
pmcid: 33185990
Wienbergen H, Pfister O, Hochadel M et al (2019) Long-term effects of iron deficiency in patients with heart failure with or without anemia: the RAID-HF follow-up study. Clin Res Cardiol 108:93–100
pubmed: 30003365
doi: 10.1007/s00392-018-1327-y
pmcid: 30003365
Klip IT, Comin-Colet J, Voors AA et al (2013) Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 165:575–582
pubmed: 23537975
doi: 10.1016/j.ahj.2013.01.017
pmcid: 23537975
Enjuanes C, Klip IT, Bruguera J et al (2014) Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol 174:268–275
pubmed: 24768464
doi: 10.1016/j.ijcard.2014.03.169
pmcid: 24768464
Ponikowski P, Kirwan BA, Anker SD et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396:1895–1904
pubmed: 33197395
doi: 10.1016/S0140-6736(20)32339-4
Anker SD, Butler J, Khan MS et al (2020) Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 41:2109–2117
pubmed: 32498081
doi: 10.1093/eurheartj/ehaa461
pmcid: 32498081
Nägele H, Gröene E, Stierle D et al (2021) Analysis of causes of death in patients with implanted defibrillators. Clin Res Cardiol. https://doi.org/10.1007/s00392-021-01825-y
doi: 10.1007/s00392-021-01825-y
pubmed: 33687520
pmcid: 33687520
Rørth R, Dewan P, Kristensen SL et al (2019) Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clin Res Cardiol 108:868–877
pubmed: 30689020
pmcid: 6652172
doi: 10.1007/s00392-019-01415-z
Linhart M, Doltra A, Acosta J et al (2020) Ventricular arrhythmia risk is associated with myocardial scar but not with response to cardiac resynchronization therapy. Europace 22:1391–1400
pubmed: 32898254
doi: 10.1093/europace/euaa142
pmcid: 32898254
Gras M, Bisson A, Bodin A et al (2020) Mortality and cardiac resynchronization therapy with or without defibrillation in primary prevention. Europace 22:1224–1233
pubmed: 32594143
doi: 10.1093/europace/euaa096
Wintrich W, Kindermann I, Ukena C et al (2020) Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clin Res Cardiol 109:1079–1098
pubmed: 32236720
pmcid: 7449942
doi: 10.1007/s00392-020-01633-w
de With RR, Rienstra M, Crijns HJGM, Van Gelder IC et al (2020) Determinants of sinus rhythm maintenance in patients with early-persistent atrial fibrillation and heart failure. Clin Res Cardiol 109:787–789
pubmed: 31784901
doi: 10.1007/s00392-019-01581-0
Anderson SG, Shoaib A, Myint PK et al (2019) Does rhythm matter in acute heart failure? An insight from the British Society for Heart Failure National Audit. Clin Res Cardiol 108:1276–1286
pubmed: 30963233
pmcid: 6805810
doi: 10.1007/s00392-019-01463-5
Hindricks G, Potpara T, Dagres N et al (2020) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 00:1126
Balla C, Cappato R (2020) Atrial fibrillation ablation in heart failure. Eur Heart J 22(Supplement E):E50–E53
doi: 10.1093/eurheartj/suaa059
Kirchhof P, Camm J, Goette A et al (2020) Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 383:1305–1316
pubmed: 32865375
doi: 10.1056/NEJMoa2019422
pmcid: 32865375
Kuck KH, Merkely B, Zahn R et al (2019) Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. Circ Arrhythm Electrophysiol. 12:e007731
pubmed: 31760819
pmcid: 31760819
Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200
pubmed: 27206819
doi: 10.1093/eurheartj/ehw128
Komajda M, Böhm M, Borer JS et al (2018) Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail 20:1315–1322
pubmed: 29806165
doi: 10.1002/ejhf.1234
pmcid: 29806165
Vaduganathan M, Claggett BL, Jhund PS et al (2020) Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet 396:121–128
pubmed: 32446323
doi: 10.1016/S0140-6736(20)30748-0
pmcid: 32446323
CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429–1435
doi: 10.1056/NEJM198706043162301
Willenheimer R, Van Veldhuisen DJ, Silke B et al (2005) Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 112:2426–2435
pubmed: 16143696
doi: 10.1161/CIRCULATIONAHA.105.582320
pmcid: 16143696
Abrahamsson P, Swedberg K, Borer JS et al (2013) Risk following hospitalization in stable chronic systolic heart failure. Eur J Heart Fail 15:885–891
pubmed: 23460732
doi: 10.1093/eurjhf/hft032
pmcid: 23460732
Gheorghiade M, Böhm M, Greene SJ et al (2013) Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309:1125–1135
pubmed: 23478743
doi: 10.1001/jama.2013.1954
pmcid: 23478743
Berg DD, Jhund PS, Docherty KF et al (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.7585
doi: 10.1001/jamacardio.2020.7585
pubmed: 33595593
pmcid: 33595593
Hidalgo FJ, Anguita M, Castillo JC et al (2016) Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study. Int J Cardiol 217:7–11
pubmed: 27167103
doi: 10.1016/j.ijcard.2016.04.136
pmcid: 27167103
Bauersachs J (2021) Heart failure drug treatment: the fantastic four. Eur Heart J 11(42):681–683
doi: 10.1093/eurheartj/ehaa1012
McMurray JJ, Packer M (2020) How should we sequence the treatments for heart failure and a reduced ejection fraction? A redefinition of evidence-based medicine. Circulation 143(9):875–877
pubmed: 33378214
doi: 10.1161/CIRCULATIONAHA.120.052926
pmcid: 33378214
McDonald M, Virani S, Chan M et al (2021) CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 37:531–546
pubmed: 33827756
doi: 10.1016/j.cjca.2021.01.017
pmcid: 33827756
Arrigo M, Jessup M, Mullens W et al (2020) Acute heart failure. Nat Rev Dis Primers 5(6):16
doi: 10.1038/s41572-020-0151-7
Rizzi MA, Sarasola AG, Arbé AA, Mateo SH et al (2020) Factors associated with in-hospital mortality and adverse outcomes during the vulnerable post-discharge phase after the first episode of acute heart failure: results of the NOVICA-2 study. Clin Res Cardiol. https://doi.org/10.1007/s00392-020-01710-0
doi: 10.1007/s00392-020-01710-0
pubmed: 32959081
Filippatos G, Angermann CE, Cleland JGF et al (2020) Global differences in characteristics, Precipitants, and initial management of patients presenting with acute heart failure. JAMA Cardiol 5:401–410
pubmed: 31913404
pmcid: 6990673
doi: 10.1001/jamacardio.2019.5108
Seferovic PM, Ponikowski P, Anker SD et al (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Failure 21:1169–1186
doi: 10.1002/ejhf.1531
Matsue Y, Damman K, Voors AA et al (2017) Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol 69:3042–3051
pubmed: 28641794
doi: 10.1016/j.jacc.2017.04.042
pmcid: 28641794
Kobayashi M, Girerd N, Duarte K et al (2021) Estimated plasma volume status in heart failure: clinical implications and future directions. Clin Res Cardiol. https://doi.org/10.1007/s00392-020-01794-8
doi: 10.1007/s00392-020-01794-8
pubmed: 34013386
pmcid: 34013386
Mentz RJ, O’Connor CM (2016) Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol 13:28–35
pubmed: 26370473
doi: 10.1038/nrcardio.2015.134
pmcid: 26370473
Böhm M, Komajda M, Borer JS, SHIFT Investigators (2018) Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. Eur J Heart Fail 20:373–381
pubmed: 29027329
doi: 10.1002/ejhf.1021
pmcid: 29027329